TY - JOUR
T1 - Effect of IV ferric carboxy maltose for moderate/severe anemia
T2 - a systematic review and meta-analysis
AU - Khatib, Mahalaqua Nazli
AU - Sinha, Anju
AU - Gaidhane, Shilpa
AU - Upadhyay, Shilpa
AU - Waghmare, Nikita
AU - Anil, Abhishek
AU - Saxena, Deepak
AU - Sawleshwarkar, Shailendra
AU - Simkhada, Padam Prasad
AU - Gaidhane, Abhay
AU - Quazi, Zahiruddin Syed
N1 - Funding Information:
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This systematic review was funded by the Indian Council of Medical Research (ICMR), Department of Health Research, Ministry of Health and Family Welfare, Government of India, New Delhi, India. Grant Number: 5/7/594/1/-RHN.
Publisher Copyright:
Copyright © 2024 Khatib, Sinha, Gaidhane, Upadhyay, Waghmare, Anil, Saxena, Sawleshwarkar, Simkhada, Gaidhane and Quazi.
PY - 2024/2/9
Y1 - 2024/2/9
N2 - INTRODUCTION: Anemia remains a prevalent global health issue with varying severity. Intravenous iron supplementation, particularly with ferric carboxymaltose (FCM), has appeared as a possible therapeutic intervention for individuals with moderate to severe anemia. The study aimed to assess the efficacy and safety of ferric carboxymaltose (FCM) in reducing anemia.METHODS: We searched electronic databases, registries, websites, e-libraries, reference lists of reviews, citations, etc. We included randomized control trials (RCTs), non-RCTs, and single-arm studies, while observational studies, case series, and case studies were excluded. Two reviewers independently screened the studies and extracted the data. We included studies of moderate-to-severely anemic Indians and excluded Indians with other comorbidities. We assessed the risk of bias and the overall quality of evidence (QoE) using GRADE GDT.RESULT: We identified 255 studies and included 14 studies (11 RCT, one non-RCT, and two single-arm studies) with 1,972 participants for qualitative analysis and 10 studies in the meta-analysis. All the included studies detailed the use of FCM for anemia. The primary outcomes assessed in the included studies were anemia, hemoglobin, and adverse events. The outcomes assessed ranged from 2 weeks to 12 weeks. The risk of bias varied across different studies with different outcomes. FCM is consistent with a fewer number of adverse events as compared to other interventions and provides "moderate" to "very low" QoE.CONCLUSION: A slow single infusion of 1 gram of FCM is well-tolerated, safe, and effective in treating iron deficiency anemia (IDA) and surpasses other interventions (Iron Sucrose Complex (ISC), Iron sucrose, and ferrous ascorbate) in elevating hemoglobin levels and replenishing iron stores.SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=459363, CRD42023459363.
AB - INTRODUCTION: Anemia remains a prevalent global health issue with varying severity. Intravenous iron supplementation, particularly with ferric carboxymaltose (FCM), has appeared as a possible therapeutic intervention for individuals with moderate to severe anemia. The study aimed to assess the efficacy and safety of ferric carboxymaltose (FCM) in reducing anemia.METHODS: We searched electronic databases, registries, websites, e-libraries, reference lists of reviews, citations, etc. We included randomized control trials (RCTs), non-RCTs, and single-arm studies, while observational studies, case series, and case studies were excluded. Two reviewers independently screened the studies and extracted the data. We included studies of moderate-to-severely anemic Indians and excluded Indians with other comorbidities. We assessed the risk of bias and the overall quality of evidence (QoE) using GRADE GDT.RESULT: We identified 255 studies and included 14 studies (11 RCT, one non-RCT, and two single-arm studies) with 1,972 participants for qualitative analysis and 10 studies in the meta-analysis. All the included studies detailed the use of FCM for anemia. The primary outcomes assessed in the included studies were anemia, hemoglobin, and adverse events. The outcomes assessed ranged from 2 weeks to 12 weeks. The risk of bias varied across different studies with different outcomes. FCM is consistent with a fewer number of adverse events as compared to other interventions and provides "moderate" to "very low" QoE.CONCLUSION: A slow single infusion of 1 gram of FCM is well-tolerated, safe, and effective in treating iron deficiency anemia (IDA) and surpasses other interventions (Iron Sucrose Complex (ISC), Iron sucrose, and ferrous ascorbate) in elevating hemoglobin levels and replenishing iron stores.SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=459363, CRD42023459363.
KW - ferric carboxymaltose
KW - iron deficiency anemia
KW - intravenous iron supplementation
KW - moderate to severe anemia
KW - hemoglobin
UR - http://www.scopus.com/inward/record.url?scp=85185917790&partnerID=8YFLogxK
U2 - 10.3389/fmed.2024.1340158
DO - 10.3389/fmed.2024.1340158
M3 - Review article
C2 - 38405188
VL - 11
JO - Frontiers in Medicine
JF - Frontiers in Medicine
SN - 2296-858X
M1 - 1340158
ER -
